Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia.
Kunlin PeiHaoyu XuPengfei WangWening GanZhengbin HuXiaoling SuHui ZhangYingyi He
Published in: Cancer medicine (2023)
A preliminary similar efficacy/safety index was observed in anti-CLL1-based CAR T-cells with 4-1BB or CD28/CD27 co-stimulatory elements in treating pediatric R/R-AML.